References
- GLOBOCAN. International Agency for Research on Cancer. 2008. Available at http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900. Accessed 23 January 2012
- Belot A, Grosclaude P, Bossard N, et al. Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique 2008;56:159-75
- Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009;14:320-68
- Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
- EMA - European public assessment report on trastuzumab (EPAR). 2000. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000278/human_med_000818.jsp&mid=WC0b01ac058001d124. Accessed 29 September 2011.
- von MG, du BA, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 2009;27:1999-2006
- von MG, Schwedler K, Schmidt M, et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer 2011;47:2273-81
- Poncet B, Colin C, Bachelot T, et al. Treatment of metastatic breast cancer: a large observational study on adherence to French prescribing guidelines and financial cost of the anti-HER2 antibody trastuzumab. Am J Clin Oncol 2009;32:369-74
- Waddell T, Kotsori A, Constantinidou A, et al. Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience. Br J Cancer 2011;104:1675-9
- Huober J, Baumann M, Rochlitz C, et al. Trastuzumab treatment beyond progression in advanced breast cancer: patterns of care in six Swiss breast cancer centers. Oncology 2011;81:160-6
- Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43
- EMA - European public report assessement (EPAR) on lapatinib. 2008. Available at http://www.ema.europa.eu/ma/index.jsp?curl=pages/medicines/human/medicines/000795/human_med_001120.jsp&mid=WC0b01ac058001d124. Accessed 29 September 2011
- Benjamin L, Cotte FE, Philippe C, et al. Physicians' preferences for prescribing oral and intravenous anticancer drugs: A Discrete Choice Experiment. Eur J Cancer 2011;48:912-20
- Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-5
- Vergnenègre A. Prescription de la chimiothérapie orale: comment valoriser cet acte spécifique du cancérologue avec le nouveau mode de financement T2A?. Le Nouveau Cancérologue 2008;1:125-33
- Johnson PE. Changes in reimbursement rates and rules associated with the Medicare Prescription Drug Improvement and Modernization Act. Introduction. Am J Health Syst Pharm 2006;63(21 Suppl 7):S2-S6
- Weingart SN, Brown E, Bach PB, et al. NCCN Task Force Report: oral chemotherapy. J Natl Compr Canc Netw 2008 Mar;6(Suppl 3):S1-S14
- Le QA, Hay JW. Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer 2009;115:489-98
- Delea TE, Tappenden P, Sofrygin O, et al. Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab. Eur J Health Econ 2011;48:721-8
- Dee A, Hutchinson M, De La Harpe D. A budget impact analysis of natalizumab use in Ireland. Ir J Med Sci 2011;181:199-204
- Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices–budget impact analysis. Value Health 2007;10:336-47
- Benjamin L, Cotte FE, Mercier F, et al. Burden of breast cancer with brain metastasis: a French national hospital database analysis. J Med Econ 2012;15:493-9
- Haute Autorité de Santé. Avis de la Commission de Transparence du 16 juillet 2008. Tyverb. Available at http://www.has-sante.fr/portail/upload/docs/application/pdf/2008-08/ct-5358_tyverb.pdf. HAS. Accessed 29 September 2011
- Extra JM, Antoine EC, Vincent-Salomon A, et al. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist 2010;15:799-809
- INCa. Situation de la chimiothérapie des cancers en 2010. Collection Rapports & synthèses, ouvrage collectif édité par l'INCa, Boulogne-Billancourt. 2010. Available at http://www.e-cancer.fr/toutes-les-actualites/360/4615-un-rapport-inca-sur-la-situation-de-la-chimiotherapie-en-2010. Accessed 25 July 2011
- Kroep JR, Linn SC, Boven E, et al. Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer. Neth J Med 2010;68:371-6
- Ameli.fr. Tarifs conventionnels des médecins généralistes en France métropolitaine. Available at http://www.ameli.fr/professionnels-de-sante/medecins/votre-convention/tarifs/tarifs-conventionnels-des-medecins-generalistes/tarifs-des-medecins-generalistes-en-metropole.php. Accessed 3 November 2011
- Ameli.fr. Tarifs conventionnels des médecins spécialistes. Available at http://www.ameli.fr/professionnels-de-sante/medecins/votre-convention/tarifs/tarifs-conventionnels-des-medecins-specialistes/les-tarifs-des-medecins-specialistes/tarifs-des-medecins-specialistes-en-metropole.php. Accessed 3 November 2011
- CNAMTS. Codage des actes de biologie (NABM). Available at www.codage.ext.cnamts.fr. CNAMTS. Accessed 3 November 2011
- Ameli.fr. Codage des actes médicaux (CCAM). Available at http://www.ameli.fr/professionnels-de-sante/directeurs-d-etablissements-de-sante/codage/codage-des-actes-medicaux-ccam.php. Accessed 3 November 2011
- CNAMTS. Base des médicaments et informations tarifaires (BDM). Available at http://www.ameli.fr/professionnels-de-sante/directeurs-d-etablissements-de-sante/codage/medicaments/base-des-medicaments-et-informations-tarifaires.php. Accessed 3 November 2011
- Rezai K, Urien S, Isambert N, et al. Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. Cancer Chemother Pharmacol 2011;68:1529-36
- Agence Française de sécurié sanitaire des produits de santé (Afssaps). Avis de la Commission de Transparence du 28 mars 2001. Herceptin. Available at http://www.has-sante.fr/portail/jcms/c_398959/herceptin-150-mg-poudre-pour-solution-a-diluer-pour-perfusion-boite-de-1?xtmc=&xtcr=37. Accessed 29 September 2011
- Weill A, Chinaud F, Vallier N, et al. Frequency and cost of the thirty long-term disorders in the Midi-Pyrénées region in 2003. Rev Med Ass Maladie 2005;36:237-287
- Commission Européenne. Eurostat: évolution des taux d'inflation. Available at http://epp.eurostat.ec.europa/inflation_dashboard/#. Accessed 5 December 2011
- Agence technique de l'information sur l'hospitalisation (ATIH). Statistiques en ligne issues de la base PMSI en HAD. Available at www.atih.sante.fr. Accessed 5 December 2011
- Buthion V, Lagrange T, Fanidi A. La chimiothérapie à domicile: complémentarité ou concurrence dans la stratégie des structures hospitalières?. Journal d'Economie Médicale 2011;29:19-36
- Agence technique de l'information sur l'hospitalisation (ATIH). Valeurs nationales de coûts HAD 2009. Available at www.atih.sante.fr. Accessed 5 December 2011
- Twelves C, Boyer M, Findlay M, . (Xeloda Colorectal Cancer Study Group). Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 2001;37:597-604
- Jansman FG, Postma MJ, van Hartskamp D, et al. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clin Ther 2004;26:579-589
- Cassidy J, Douillard JY, Twelves C, et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer 2006;94:1122-1129
- Lau BD, Pinto BL, Thiemann DR, et al. Budget impact analysis of conversion from intravenous to oral medication when clinically eligible for oral intake. Clin Ther 2011;33:1792-6
- Purdie CA BLAA. Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study. Br J Cancer 2010;4:475-81
- Journal officiel de la République française (JORF). Arrêté du 1er mars 2011 fixant pour l'année 2011 les éléments tarifaires mentionnés aux I et IV de l'article L. 162-22-10 du code de la sécurité sociale et aux IV et V de l'article 33 modifié de la loi de financement de la sécurité sociale pour 2004. 2011. Available at www.legifrance.gouv.fr. Accessed 25 July 2011